Safety, Tolerability, and Pharmacokinetics of the Mineralocorticoid Receptor Modulator AZD9977 in Healthy Men: A Phase I Multiple Ascending Dose Study

by Andrew Whittaker, Åsa M. Kragh, Judith Hartleib‐Geschwindner, Muna Albayaty, Anna Backlund, Peter J. Greasley, Maria Heijer, Magnus Kjaer, Pablo Forte, Robert Unwin, Linda Wernevik, Hans Ericsson
Published 2020-03-01

Early Clinical Experience With AZD4831, A Novel Myeloperoxidase Inhibitor, Developed for Patients With Heart Failure With Preserved Ejection Fraction

by Karin Nelander, Maria Lagerstrom‐Fermer, Carl Amilon, Erik Michaëlsson, Maria Heijer, Magnus Kjaer, Muir Russell, David Han, Eva‐Lotte Lindstedt, Carl Whatling, Li‐Ming Gan, Hans Ericsson
Published 2021-05-01

Exploring the insulin secretory properties of the PGD2-GPR44/DP2 axis in vitro and in a randomized phase-1 trial of type 2 diabetes patients.

by Stanko Skrtic, Björn Tyrberg, Malin Broberg, Hans Ericsson, Volker Schnecke, Magnus Kjaer, Marcus Hompesch, Eva-Marie Andersson, Erik Ryberg, Alexander Aivazidis, Charlotte Wennberg Huldt, Lars Löfgren, Linda Morrow, Joanna Parkinson, Tina Rydén-Bergsten, Elaine Watkins, Maria Sörhede Winzell
Published 2018-01-01